Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market To be extracted
Other Market Stock Code To be extracted
H-Share Offer PriceHK$ 648.00
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameZai Lab
Stock Code09688
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities創新型、立足研發及處於商業階段的生物製藥公司,專注於發現、授權、開發及商業化療法,解決中國及全球市場的巨大醫療需求缺口,包括腫瘤、抗感染及自體免疫性疾病領域。
Listing Date2020-09-28
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東區金科路4560號1號樓4樓
Business Address (Hong Kong)香港北角英皇道510號港運大廈23樓2301室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.zailaboratory.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingYes (NASDAQ)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 648.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size50 shares
Entry ThresholdHK$ 32,400
Par ValueTo be extracted
Offer Period2020-09-17 to 2020-09-22
Global Offering Shares10,564,050 shares
HK Public Offer Shares (Initial)771,700 shares (7.3%)
Public Offer Lots (Initial)15,434lots (Pool A7,717lots,Pool B7,717lots)
International Placing Shares (Initial)9,792,350 shares (92.7%)
Offer Ratio~7.3%
Total Shares Post-IPO85,939,561 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 6,845,504,400

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 50 HK$ 32,400
2 lots 100 HK$ 64,800
3 lots 150 HK$ 97,200
4 lots 200 HK$ 129,600
5 lots 250 HK$ 162,000
6 lots 300 HK$ 194,400
7 lots 350 HK$ 226,800
8 lots 400 HK$ 259,200
9 lots 450 HK$ 291,600
10 lots 500 HK$ 324,000
12 lots 600 HK$ 388,800
14 lots 700 HK$ 453,600
16 lots 800 HK$ 518,400
18 lots 900 HK$ 583,200
20 lots 1,000 HK$ 648,000
30 lots 1,500 HK$ 972,000
40 lots 2,000 HK$ 1,296,000
50 lots 2,500 HK$ 1,620,000
60 lots 3,000 HK$ 1,944,000
70 lots 3,500 HK$ 2,268,000
80 lots 4,000 HK$ 2,592,000
90 lots 4,500 HK$ 2,916,000
100 lots 5,000 HK$ 3,240,000
110 lots 5,500 HK$ 3,564,000
120 lots 6,000 HK$ 3,888,000
130 lots 6,500 HK$ 4,212,000
140 lots 7,000 HK$ 4,536,000
150 lots 7,500 HK$ 4,860,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
160 lots 8,000 HK$ 5,184,000
170 lots 8,500 HK$ 5,508,000
180 lots 9,000 HK$ 5,832,000
200 lots 10,000 HK$ 6,480,000
400 lots 20,000 HK$ 12,960,000
600 lots 30,000 HK$ 19,440,000
800 lots 40,000 HK$ 25,920,000
6,000 lots 300,000 HK$ 194,400,000
7,717 lots 385,850 HK$ 250,030,800

Stock Connect Inclusion Analysis

HK Market Cap HK$ 21.04B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 55,688,835,528
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损约195.1百万美元
Period-End Cash Balance275.9百万美元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment約164.6百萬美元

Financial Data

Unit: '000 USD
Income Statement
Item 20182019
Revenue 12912,985
Cost of sales -43-3,749
Other income and gains, net 59938
Administrative expenses -21,576-70,211
Operating profit -141,768-203,196
Share of associates and JVs -587-752
Profit before tax -138,488-194,319
Income tax expense 00
Profit for the year -139,075-195,071
Profit attributable to owners -139,075-195,071
Balance Sheet
Item 201820192020-06
Cash and cash equivalents 62,95275,932
Trade and bills receivables 903,791
Inventories 46,005
Total current assets 269,145292,464
Total assets 301,987355,153
Total current liabilities 48,84246,635
Total liabilities 50,90660,493
Total equity 251,081294,660
Interest-bearing borrowings 3,6436,4504,238
Cash Flow Statement
Item 201820192020-06
Net cash from operating activities -97,538-191,011
Net cash from investing activities -212,554-14,892
Net cash from financing activities 144,147219,302
Net increase in cash -166,70813,490
Purchase of PP&E -10,015-6,035-1,303
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 610.0
First Day OpenHK$ 613.5
First Day Change8.54%
First Day Volume1075520.0
First Day Turnover648951000.0
Use of Proceeds
1、約46.2%預期將分配至我們的核心產品; 2、約11.8%預期將為進行中及計劃臨床試驗以及管線中其他候選藥物(尤其是晚期候選藥物)的準備中注冊備案撥資; 3、約25.0%預期將用于探索新的全球授權及合作機會并引進具有臨床驗證的潛在全球同類最佳/同類首創資產; 4、約7.0%預期將用于持續投資及擴大我們的內部研發產品管線以及在全球招聘及培訓高端人才; 5、約10.0%預期為營運資金及其他一般企業用途撥資。

Underwriting Syndicate

Joint Sponsors (3)
J.P. Morgan Securities (Far East) Limited CE AAB026 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Citigroup Global Markets Asia Limited CE AAA137
Overall Coordinators (4)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Citigroup Global Markets Asia Limited CE AAA137 Jefferies Hong Kong Limited CE ATS546
Joint Bookrunners (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Citigroup Global Markets Asia Limited CE AAA137 Jefferies Hong Kong Limited CE ATS546 Merrill Lynch (Asia Pacific) Limited CE AAC198 Credit Suisse (Hong Kong) Limited CE AAO017 中国国际金融香港证券有限公司 CE AEN894 海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Citigroup Global Markets Asia Limited CE AAA137 Jefferies Hong Kong Limited CE ATS546 Merrill Lynch (Asia Pacific) Limited CE AAC198 Credit Suisse (Hong Kong) Limited CE AAO017 中国国际金融香港证券有限公司 CE AEN894 海通国际证券有限公司 CE AAF806

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman杜瑩—
Company SecretaryF.Ty Edmondson—
No director data available.

Major Shareholders

Major Shareholders & HoldingsQM11 Limited持股12.0%,FMR, LLC持股9.4%,Capital Group持股7.9%,尚珹資本關聯的投資基金持股6.0%,杜瑩博士持股7.8%
About this page

This page shows Zai Lab (09688) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect